Log in to your Inderes Free account to see all free content on this page.
IRLAB Therapeutics
2.32 SEK
-1.07 %
Less than 1K followers
IRLAB A
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-1.07 %
-3.73 %
-13.91 %
-65.34 %
-77.14 %
-80.42 %
-93.84 %
-94.23 %
-78.81 %
IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.
Read moreMarket cap
197.06M SEK
Turnover
115.67K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
11.2.
2026
Annual report '25
6.5.
2026
Interim report Q1'26
20.5.
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Nomination committee appointed for IRLAB’s annual general meeting 2026
IRLAB receives acceptance for two abstracts at AD/PD™ 2026: The 20th International Conference on Alzheimer’s and Parkinson’s Diseases
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio